MedTrace Logo

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

NCT02724735 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2016-09-21

No results posted yet for this study

Summary

All subjects completing the randomized treatment period in Protocol NS2014-1 will discontinue study drug and be asked to provide consent to be followed in this 6-month study, at their final safety visit. The study will consist of an enrollment visit, followed by bi-monthly in-clinic visits with monthly telephone visits between in-clinic visits.

Conditions

Interventions

DRUG

NSI-189

0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only

Sponsors & Collaborators

  • Neuralstem Inc.

    lead INDUSTRY

Principal Investigators

  • Karl Johe, Ph.D. · Neuralstem Inc.

Eligibility

Min Age
18 Years
Max Age
61 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02724735 on ClinicalTrials.gov